Forest plot of CR + CRh rate by subgroup (adult efficacy-evaluable population). ∗One patient with an ECOG PS of 3 was included. This patient had an ECOG PS of 0 to 2 at screening per protocol but an ECOG PS of 3 on cycle 1 day 1. The most recent status before the first dose of study treatment was used for baseline characteristics. †Primary refractory disease was defined as no CR or CRi after 2 courses of intensive induction treatment, excluding patients with death during aplasia or death due to indeterminate cause.27 Refractory relapse was defined as disease remission (CR or CRi) in response to previous therapy followed by relapse but without attaining a remission with reinduction therapy. Early untreated relapse was defined as occurring <1 year after previous remission. Late untreated relapse was defined as occurring ≥1 year after remission. ECOG PS, Eastern Cooperative Oncology Group performance status; TKD, tyrosine kinase domain.
